The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma

Multiple myeloma (MM) treatment regimens have vastly improved since the introduction of immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies; however, MM is considered an incurable disease due to inevitable relapse and acquired drug resistance. Understanding the molecular mec...

Descripción completa

Detalles Bibliográficos
Autores principales: Sellin, Mark, Berg, Stephanie, Hagen, Patrick, Zhang, Jiwang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166471/
https://www.ncbi.nlm.nih.gov/pubmed/35660848
http://dx.doi.org/10.1016/j.tranon.2022.101448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166471/
https://www.ncbi.nlm.nih.gov/pubmed/35660848
http://dx.doi.org/10.1016/j.tranon.2022.101448

Ejemplares similares